Home › Blood Clots › NCT00178594
Evaluation of Hemostasis in Bleeding and Thrombotic Disorders
RecruitingObservational study
Evaluation of Hemostasis in Bleeding and Thrombotic Disorders Using the Roteg Analyzer and the Thrombin Generation Assay
Who can join
1 Day – 98 Years · All sexes
Full eligibility criteria
Inclusion Criteria: patients with congenital or acquired bleeding or clotting disorders who have provided informed consent and/or assent Exclusion Criteria: poor venous access
About the study
The objective of this study will be to assess the coagulation system in-vitro in a variety of bleeding and clotting disorders using the ROTEG analyzer and the thrombin generation assay.
Sponsor: The University of Texas Health Science Center, Houston · Participants: 1,000 · Started: 2002-10
Contact the study team
- Katherine Addy, RN, BSN, MPH · Phone: 713-500-8352
- Daisy Garcia, RN, BSN · Phone: 713-500-8386
Official record on ClinicalTrials.gov — NCT00178594
Locations in the U.S.
| Texas | The Univerisity of Texas Health Science Center at Houston, Houston UT Physicians Women's Center-Texas Medical Center, Houston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.